Moderate hyperhomocysteinaemia and immune activation in patients with rheumatoid arthritis

Clinica Chimica Acta

Volumn 338, Issue 1-2, 2003, Pages 157-164

  Schroecksnadel, Katharina ^a   Frick, Barbara ^a   Kaser, Sabine ^b   Wirleitner, Barbara ^a   Ledochowski, Maximilian ^b   Mur, Erich ^b   Herold, Manfred ^b   Fuchs, Dietmar ^a,c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Homocysteine; Immune activation; Neopterin; Oxidative stress; Rheumatoid arthritis; Vitamin deficiency

Indexed keywords

AZATHIOPRINE; CYANOCOBALAMIN; CYCLOSPORIN A; CYSTEINE; DICLOFENAC; FOLIC ACID; HOMOCYSTEINE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; LOMOXICAM; MELOXICAM; METHOTREXATE; NEOPTERIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SALAZOSULFAPYRIDINE; TRAMADOL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VITAMIN B GROUP;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0344154549     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.09.003     Document Type: Article

References (37)

1. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
2. Pettersson T., Friman C., Abrahamsson L., Nilsson B., Norberg B. Serum homocysteine and methylmalonic acid in patients with rheumatoid arthritis and cobalaminopenia. J. Rheumatol. 25:1998;859-863.
3. Roubenoff R., Dellaripa P., Nadeau M.R.et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum. 40:1997;718-722.
4. Aksu K., Turgan N., Oksel F.et al. Hyperhomocysteinaemia in Behcet's disease. Rheumatology. 40:2001;687-690.
5. Marasini B., Casari S., Bestetti A.et al. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. J. Rheumatol. 27:2000;2621-2623.
6. Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand. J. Rheumatol. 30:2001;305-307.
7. Allegra C.J., Fine R.L., Drake J.C., Chabner B.A. The effect of methothrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J. Biol. Chem. 261:1986;6478-6485.
8. Erb N., Kitas G.D. Homocysteine modulation as a reason for continuous folic acid supplementation in methotrexate-treated rheumatoid arthritis patients. Rheumatology. 40:2001;715-716.
9. Morgan S.L., Baggott J.E., Lee J.Y., Alarcon G.S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long-term, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J. Rheumatol. 25:1998;441-446.
10. Seriolo B., Fasciolo D., Sulli A., Cutolo M. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin. Exp. Rheumatol. 19:2001;561-564.
11. Wilder R.L. Rheumatoid arthritis: epidemiology, pathology and pathogenesis. Schumacher H.R. Primer on Rheumatic Diseases. 1993;86-89 Arthritis Foundation, Atlanta.
12. Cope A.P., Aderka D., Aderka D.et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic disease. Arthritis Rheum. 35:1992;1160-1169.
13. Barrera P., Boerbooms A.M., Janssen E.M.et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor-α and interleukin-6 levels in rheumatoid arthritis. Arthritis Rheum. 36:1993;1070-1079.
14. Steiner G., Studnicka-Benke A., Witzmann G., Hofler E., Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J. Rheumatol. 22:1995;406-412.
15. Keystone E.C., Snow K.M., Bombardier C., Chang C.H., Nelson D.L., Rubin L.A. Elevated soluble IL-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum. 31:1988;1358-1364.
16. Symons J.A., Wood N.C., Di Giovine F.S., Duff G.W. Soluble IL-2 receptor in rheumatoid arthritis: correlation with disease activity, IL-1 and IL-2 inhibition. J. Immunol. 141:1988;2612-2618.
17. Rubin L.A., Snow K.M., Kurman C.C., Nelson D.L., Keystone E.C. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J. Rheumatol. 17:1990;597-602.
18. Tebib J.G., Letroublon M.C., Bienvenu J., Bouvier M. sIL-2R levels in rheumatoid arthritis: poor correlation with clinical activity is due to part to disease duration. Br. J. Rheumatol. 34:1995;1037-1040.
19. Reibnegger G., Egg D., Fuchs D.et al. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. Arthritis Rheum. 29:1986;1063-1070.
20. Maerker-Alzer G., Diemer O., Strumper R., Rohe M. Neopterin production in inflamed knee joints: high levels in synovial fluids. Rheumatol. Int. 6:1986;151-154.
21. Schroecksnadel K., Frick B., Wirleitner B., Schennach H., Fuchs D. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin. Exp. Immunol. 134:2003;53-56.
22. Frick B., Schröcksnadel K., Neurauter G., Wirleitner B., Artner Dworzak E., Fuchs D. Rapid measurement of total plasma homocysteine by HPLC. Clin. Chim. Acta. 331:2003;19-23.
23. Selhub J., Jacques P.F., Rosenberg I.H.et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann. Intern. Med. 131:1999;331-339.
24. van den Brandhof W.E., Haks K., Schouten E.G., Verhoef P. The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis. 157:2001;403-409.
25. Burtis C.A., Ashwood E.R. Tietz Textbook of Clinical Chemistry. 2nd ed. 1994;2057 WB Saunders Publishers, Philadelphia.
26. Zangerle R., Gallati H., Sarcletti M.et al. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J. Acquir. Immune Defic. Syndr. 7:1994;79-85.
27. Fuchs D., Weiss G., Reibnegger G., Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit. Rev. Clin. Lab. Sci. 29:1992;307-341.
28. 12 and folate. Pteridines. 14:2003;27-34.
29. Mansoor M.A., Bergmark C., Svardal A.M., Lonning P.E., Ueland P.M. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Arterioscler. Thromb. Vasc. Biol. 15:1995;232-240.
30. Gottsater A., Forsblad J., Mattiasson I., Lindgarde F. Decreasing plasma endothelin-1 and unchanged plasma neopterin during folate supplementation in hyperhomocysteinemia. Int. Angiol. 21:2002;158-164.
31. Erren M., Reinecke H., Junker R.et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler. Thromb. Vasc. Biol. 19:1999;2355-2363.
32. Leblhuber F., Walli J., Arthner-Dworzak E.et al. Hyperhomocysteinemia in dementia. J. Neural Transm. 107:2000;1469-1474.
33. Widner B., Leblhuber F., Frick B., Laich A., Artner-Dworzak E., Fuchs D. Moderate hyperhomocysteinemia and immune activation in Parkinson's disease. J. Neural Transm. 109:2002;181-189.
34. Halliwell B., Clement M.V., Long L.H. Hydrogen peroxide in the human body. FEBS Lett. 486:2000;10-13.
35. Fuchs D., Jaeger M., Widner B., Wirleitner B., Artner-Dworzak E., Leblhuber F. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake? Clin. Chem. Lab. Med. 39:2001;691-694.
36. Mezzano D., Pais E.O., Aranda E.et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int. 60:2001;1844-1850.
37. 12 deficiency and Alzheimer disease. Neurology. 58:2002;1395-1399.